Golden State Equity Partners Invests $430,000 in The Clorox Company (NYSE:CLX)

Golden State Equity Partners purchased a new stake in shares of The Clorox Company (NYSE:CLX - Free Report) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 2,923 shares of the company's stock, valued at approximately $430,000.

Other hedge funds also recently bought and sold shares of the company. Redwood Park Advisors LLC bought a new stake in Clorox during the fourth quarter valued at about $26,000. Millstone Evans Group LLC bought a new stake in Clorox during the fourth quarter valued at about $31,000. Wood Tarver Financial Group LLC acquired a new position in shares of Clorox during the fourth quarter valued at about $31,000. GKV Capital Management Co. Inc. acquired a new position in shares of Clorox during the fourth quarter valued at about $32,000. Finally, Aster Capital Management DIFC Ltd acquired a new position in shares of Clorox during the fourth quarter valued at about $33,000. 78.53% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on CLX shares. UBS Group cut their price objective on shares of Clorox from $176.00 to $154.00 and set a "neutral" rating for the company in a research report on Thursday, April 17th. Citigroup cut their price objective on shares of Clorox from $165.00 to $150.00 and set a "neutral" rating for the company in a research report on Monday, April 14th. Wells Fargo & Company cut their price objective on shares of Clorox from $145.00 to $142.00 and set an "equal weight" rating for the company in a research report on Tuesday, May 6th. Morgan Stanley cut their price objective on shares of Clorox from $165.00 to $150.00 and set an "equal weight" rating for the company in a research report on Tuesday, May 6th. Finally, Barclays cut their price objective on shares of Clorox from $134.00 to $129.00 and set an "underweight" rating for the company in a research report on Wednesday, May 7th. Three analysts have rated the stock with a sell rating, ten have assigned a hold rating and one has issued a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $149.50.

Clorox Price Performance

NYSE:CLX traded up $1.08 during mid-day trading on Friday, hitting $119.09. The company's stock had a trading volume of 5,265,025 shares, compared to its average volume of 1,384,357. The Clorox Company has a fifty-two week low of $117.35 and a fifty-two week high of $171.37. The company has a current ratio of 0.74, a quick ratio of 0.44 and a debt-to-equity ratio of 13.07. The company has a market capitalization of $14.68 billion, a price-to-earnings ratio of 21.38, a P/E/G ratio of 2.70 and a beta of 0.54. The stock has a fifty day moving average of $131.62 and a 200-day moving average of $145.61.

Clorox (NYSE:CLX - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The company reported $1.45 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.12). The firm had revenue of $1.67 billion for the quarter, compared to analyst estimates of $1.74 billion. Clorox had a return on equity of 324.23% and a net margin of 9.89%. The business's quarterly revenue was down 8.0% on a year-over-year basis. During the same period in the previous year, the business posted $1.71 EPS. As a group, equities analysts forecast that The Clorox Company will post 7.15 EPS for the current fiscal year.

Insider Transactions at Clorox

In other news, Director Pierre R. Breber acquired 4,000 shares of the company's stock in a transaction dated Wednesday, May 7th. The stock was bought at an average price of $136.57 per share, with a total value of $546,280.00. Following the completion of the acquisition, the director now owns 4,000 shares in the company, valued at approximately $546,280. This represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 0.57% of the company's stock.

Clorox Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.